JP2006506994A5 - - Google Patents

Info

Publication number

JP2006506994A5

JP2006506994A5 JP2004554468A JP2004554468A JP2006506994A5 JP 2006506994 A5 JP2006506994 A5 JP 2006506994A5 JP 2004554468 A JP2004554468 A JP 2004554468A JP 2004554468 A JP2004554468 A JP 2004554468A JP 2006506994 A5 JP2006506994 A5 JP 2006506994A5

Authority

JP

Japan

Prior art keywords

polypeptide

amino acid

thr

antibody

seq

Prior art date

2003-11-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108091000080 Phosphotransferase Proteins 0.000 claims description 7
• 102000020233 phosphotransferase Human genes 0.000 claims description 7
• 230000000694 effects Effects 0.000 claims description 4
• 101100133106 Mus musculus Ndrg2 gene Proteins 0.000 claims description 2
• 101150032346 NDRG1 gene Proteins 0.000 claims description 2
• 125000000539 amino acid group Chemical group 0.000 claims description 2
• 229920001184 polypeptide Polymers 0.000 claims 15
• 102000004196 processed proteins & peptides Human genes 0.000 claims 15
• 108090000765 processed proteins & peptides Proteins 0.000 claims 15
• 150000001413 amino acids Chemical class 0.000 claims 9
• 125000003275 alpha amino acid group Chemical group 0.000 claims 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 239000000356 contaminant Substances 0.000 claims 2
• XMBSYZWANAQXEV-QWRGUYRKSA-N Glu-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-QWRGUYRKSA-N 0.000 claims 1
• XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims 1
• 230000002378 acidificating effect Effects 0.000 claims 1
• 239000011230 binding agent Substances 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 238000002955 isolation Methods 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 239000002689 soil Substances 0.000 claims 1
• 101000701401 Homo sapiens Serine/threonine-protein kinase 38 Proteins 0.000 description 5
• 102100030514 Serine/threonine-protein kinase 38 Human genes 0.000 description 5
• 101000979748 Homo sapiens Protein NDRG1 Proteins 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 101001045553 Homo sapiens Hemogen Proteins 0.000 description 2
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 101000697608 Homo sapiens Serine/threonine-protein kinase 38-like Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102100027898 Serine/threonine-protein kinase 38-like Human genes 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 102000057348 human HEMGN Human genes 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1